Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast

Jaguar Health, Inc.

Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.
No approved drug treatments for MVID, an ultrarare pediatric disease.
Webcast on April 30, 2025 at 8:30 AM ET; includes KOL commentary.
Ongoing POC IITs (3) and Phase 2 studies (2) for crofelemer in MVID and SBS-IF.
Possible expedited regulatory pathways for crofelemer in MVID discussed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.